Bank of Nova Scotia trimmed its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,754 shares of the biopharmaceutical company’s stock after selling 676 shares during the period. Bank of Nova Scotia’s holdings in Alexion Pharmaceuticals were worth $6,175,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Neuberger Berman Group LLC grew its position in Alexion Pharmaceuticals by 29.9% during the 1st quarter. Neuberger Berman Group LLC now owns 6,189 shares of the biopharmaceutical company’s stock worth $750,000 after purchasing an additional 1,423 shares during the last quarter. Teachers Advisors LLC grew its position in Alexion Pharmaceuticals by 3.0% during the 1st quarter. Teachers Advisors LLC now owns 422,267 shares of the biopharmaceutical company’s stock worth $51,196,000 after purchasing an additional 12,179 shares during the last quarter. South Dakota Investment Council purchased a new position in Alexion Pharmaceuticals during the 1st quarter worth $1,115,000. Ngam Advisors L.P. grew its position in Alexion Pharmaceuticals by 6.3% during the 1st quarter. Ngam Advisors L.P. now owns 13,618 shares of the biopharmaceutical company’s stock worth $1,651,000 after purchasing an additional 808 shares during the last quarter. Finally, Pictet & Cie Europe SA purchased a new position in Alexion Pharmaceuticals during the 1st quarter worth $1,476,000. 94.25% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at 140.61 on Monday. The stock’s 50 day moving average is $142.24 and its 200-day moving average is $127.19. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34. The stock has a market capitalization of $31.38 billion, a P/E ratio of 60.98 and a beta of 1.39.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The company had revenue of $912.00 million during the quarter, compared to analyst estimates of $846.15 million. During the same period in the prior year, the firm earned $1.13 earnings per share. The business’s quarterly revenue was up 21.1% on a year-over-year basis. On average, equities research analysts expect that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current year.

In other news, Director Ann M. Veneman sold 835 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total value of $121,751.35. Following the completion of the sale, the director now directly owns 5,480 shares of the company’s stock, valued at $799,038.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Julie O’neill sold 11,160 shares of the stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the completion of the sale, the executive vice president now directly owns 26,704 shares of the company’s stock, valued at $3,738,560. The disclosure for this sale can be found here. Insiders have sold 17,190 shares of company stock valued at $2,433,669 over the last ninety days. Insiders own 4.35% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/alexion-pharmaceuticals-inc-alxn-position-lowered-by-bank-of-nova-scotia/1634336.html.

Several research analysts have issued reports on ALXN shares. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 price objective on the stock in a research report on Wednesday, August 2nd. Oppenheimer Holdings, Inc. raised shares of Alexion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $175.00 price objective on the stock in a research report on Friday, July 28th. Royal Bank Of Canada started coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $161.00 price objective on the stock. Morgan Stanley reissued an “overweight” rating and set a $153.00 price objective (up from $141.00) on shares of Alexion Pharmaceuticals in a research report on Friday, July 28th. Finally, TheStreet raised shares of Alexion Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Friday, July 14th. Six investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $154.56.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.